Literature DB >> 17610536

Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.

Joseph Chacko1, Dudley J Pennell, Mark A Tanner, Terry J Hamblin, Beatrix Wonke, Terry Levy, Peter W Thomas, Sally B Killick.   

Abstract

Magnetic resonance imaging (MRI) was used to quantify myocardial iron loading by T2* in 11 transfusion-dependent good prognostic myelodysplastic syndrome (MDS) patients. Myocardial T2*, left ventricular function and hepatic T2* were measured simultaneously. Patients had been on transfusion therapy for 13-123 months and had serum ferritin levels of 1109-6148 microg/l at the time of study. Five patients had not commenced iron chelation and had been transfused with a median of 63 red cell units and had a median serum ferritin level of 1490 microg/l. Six patients were on iron chelation and had been transfused with a median of 112 red cell units and had a median serum ferritin level of 4809 mug/l. Hepatic iron overload was mild in two, moderate in seven and severe in two patients. The median liver iron concentration was 5.9 mg/g dry weight in chelated patients and 9.5 mg/g in non-chelated patients (P = 0.17; not significant). Myocardial T2* indicated absent iron loading in 10/11 patients (91%; 95% confidence interval 62-98%) and borderline-normal in one patient. Left ventricular function was normal in all patients. No correlation was observed between increasing serum ferritin levels, hepatic iron overload and myocardial T2*. A long latent period relative to hepatic iron loading appears to predate the development of myocardial iron loading in transfusion-dependent MDS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610536     DOI: 10.1111/j.1365-2141.2007.06695.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

Review 3.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 4.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

5.  Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.

Authors:  Alessia Pepe; Michele Rizzo; Sara Galimberti; Claudia Baratè; Esther Natalie Oliva; Francesco Arcioni; Sergio Storti; Stefania Renne; Massimo Midiri; Gennaro Restaino; Vincenzo Positano; Maurizio Mangione; Antonella Meloni
Journal:  Ann Hematol       Date:  2021-03-19       Impact factor: 3.673

Review 6.  The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 7.  Cardiac iron across different transfusion-dependent diseases.

Authors:  John C Wood
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250

8.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

9.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.